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stratiﬁ cation to mono- or adjunct therapy. Outcome variables were patient- and physi-
cian-reported treatment SEU ratings at weeks 4 and 12. Predictors included change
from baseline in the bradykinesia subscale of the Uniﬁ ed Parkinson’s Disease Rating
Scale, change from baseline in patient- and physician-reported Activities of Daily 
Living (ADL), and patient- and physician-reported Clinical Global Impression (CGI).
Data were analyzed using linear regression. RESULTS: SEU ratings with rasagiline 
were positive at all visits. Complete data were available for 109 monotherapy and 
131 adjunct therapy patients at week 12. Patient- and physician-reported CGI 
were positively related to SEU ratings reported by the same individual at the same 
visit (p  0.05); patient-reported CGI was positively related to physician-reported SEU
ratings at week 4 (p  0.05). Bradykinesia improvement from baseline predicted physi-
cian-reported SEU ratings at week 4 for monotherapy (p  0.01). Patient-reported
ADL improvement from baseline predicted patient-reported SEU ratings at week 12 
for adjunct therapy (p  0.01). CONCLUSIONS: Patient- and physician-reported CGI 
were consistently related to patient- and physician-reported SEU ratings with rasagi-
line. Furthermore, improvement in bradykinesia symptoms and patient-reported ADL
predicted subsequent ratings of treatment SEU in some cases. Additional research on 
patient- and physician-reported treatment SEU scales in PD populations is needed to 
reﬁ ne this important endpoint.
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EPIDEMIOLOGIC CHARACTERISTICS AND HEALTH RESOURCE USE IN 
A MULTIPLE SCLEROSIS CENTER IN SAO PAULO, BRAZIL
Sato DK, Apostolos-Pereira SL, Junqueira TF, Adoni T, Lino AM, Marchiori PE, Callegaro D
University of Sao Paulo, Sao Paulo, SP, Brazil
OBJECTIVES: Multiple Sclerosis (MS) is an immunomediated, highly disabling
disease affecting young adults. The demographic characteristics, disease modifying 
therapies and health resources utilization by patients followed at a MS reference center
in Sao Paulo, Brazil are presented. METHODS: Patient’s charts were reviewed from 
a retrospective cohort of 353 MS patients. Patients were selected by attendance to 
outpatient visits at Hospital das Clínicas, Faculty of Medicine – University of Sao 
Paulo from March to May 2008. RESULTS: From 353 patients, 74% were female
and 86% were white-Caucasians. A positive family history was identiﬁ ed in ﬁ ve
patients. Sixty-eight percent had relapsing-remitting MS, 13% secondary progressive
MS and 10% primary progressive MS. Half of the patients had MS diagnosis for less 
than 5 years. At the last interview, 226 patients (64%) were on immunomodulatory
agents. From these, 59 patients were using glatiramer acetate and 167 were using 
beta-interferons. The immunomodulatory drug was changed in 11 patients. Sixty-one 
patients (17%) were on immunossupressants, with 31% using azathioprine. Average 
EDSS score at last visit was 4.2. Approximately 24% of patients had at least one 
relapse requiring treatment and 5% were hospitalized in the last 12 months. CON-
CLUSIONS: There are few data on epidemiology and health resource use published 
in Latin-American countries, while many countries like Brazil provide high-cost treat-
ments at public health system. In our study, the current approved MS therapies were
widely used. Therefore, the understanding of local patients’ characteristics and health 
resources use can provide data for an optimized, tailored disease management solu-
tions in these countries.
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DISEASE BURDEN AND TREATMENT PATTERNS OF PARKINSON’S 
DISEASE IN A LONG TERM CARE SETTING
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OBJECTIVES: Examine the patient characteristics, treatment patterns and cost of care
among Parkinson’s Disease (PD) residents in a long term care (LTC) setting, speciﬁ -
cally, skilled nursing facilities (SNFs) in the US. PD is a progressive neurodegenerative
disorder that produces considerable morbidity. The prevalence and incidence of PD 
increase with age. PD affects more than 3% of individuals over 65 years old.
METHODS: Retrospective analysis of PD patients in SNFs from June 2004–2008.
Using a large provider database, 7885 PD patients were identiﬁ ed. Patient demograph-
ics, comorbidities, treatment patterns and costs were assessed using administrative and 
clinical databases at baseline and one year (1 year). RESULTS: A total of 4150 PD 
patients with baseline and 1 year data constituted the analysis cohort, mean age of 
82 years, 46% male and 57% admitted from an acute care hospital. At baseline, 43%
had fallen in the past 30 days, 94% reported bathing assistance; 24% and 38% were
bladder and bowel continent; 71% and 44% suffered short and long-term memory 
loss. Patients received speech, occupational and physical therapy for 68, 153 and 157
minutes per week. The average patient had 6 comorbid conditions: hypertension
(64%), depression (46%), dementia (43%) and diabetes (31%) were common. 83%
were diagnosed with PD before or at SNF admission. At baseline, 79% were PD 
medication-free; 49% remained PD medication-free over 1y. Patients averaged 11
medications. Concomitant medication use of analgesics, antihypertensives and antide-
pressants were the most common. Direct LTC monthly medical costs were $5355 and
$6097 at baseline and 1 year. CONCLUSIONS: PD patients have physical and cogni-
tive impairment, combined with debilitating comorbidities. Falls, incontinence, 
memory loss, hypertension, depression, dementia and diabetes complicate PD treat-
ment in LTC. Concomitant medication burden further complicates treatment. Ongoing
examination into treatment needs and barriers to PD medication use is needed to
alleviate PD burden in LTC.
PND35
SOCIOECONOMIC FACTORS OF INSOMNIA PRESCRIPTION IN A 
NATIONAL DATABASE
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OBJECTIVES: Our study aims to identify socioeconomic factors related to insomnia
prescription patterns in US outpatient settings. METHODS: This project proposes a 
secondary data analysis using a national longitudinal database from 2004 National 
Ambulatory Medical Care Survey (NAMCS). Study subjects were derived from out-
patient visits in which at least one insomnia drug was prescribed. A series of weighted
chi-square statistics were performed to compare insomnia drug uses across various
physician and patient characteristics. All analyses used SAS statistical software and 
incorporated sample weights and standard errors correction. RESULTS: Among the 
910 million outpatient visits that took place in the US in 2004, an estimated 24.
98 million visits included at least one insomnia drug prescription. The majority of 
prescriptions were allocated to antidepressants (52.3%), which were more frequently 
prescribed than non-benzodiazepines (34.1%) and benzodiazepines (13.6%). Differ-
ences in drug pricing may explain these ﬁ ndings: the average wholesale price (AWP) 
for antidepressants is lower ($0.31) than non-benzodiazepine hypnotics ($2.52). 
Patient comparisons by insurance type revealed that Medicaid patients were less likely 
to receive the relatively expensive non-benzodiazepines (27.55%) than Medicare 
(32.53%), self-pay (33.39%), and private insurance (35.03%) patients. Prescribing
patterns were signiﬁ cantly inﬂ uenced by physician specialty (P  0.0001), with general/
family physicians contributing the greatest frequency of insomnia prescriptions 
(36.1%). Females received signiﬁ cantly more insomnia prescriptions than males (16.4
mil. vs. 8.58 mil.; P  0.0001) and Black/Hispanics received signiﬁ cantly fewer
insomnia prescriptions than did white patients (10.78% vs. 87.13%, P  0.0001). 
CONCLUSIONS: Our ﬁ ndings indicate signiﬁ cant socioeconomic disparities in the 
use of insomnia prescriptions. While drug pricing might account for some of our 
results, marketing—particularly the sociodemographic and physician characteristics
toward which such efforts are targeted—provides another strong explanation for
prescription pattern disparities. Further evaluation of current practice guidelines and
development of more manageable regulations might ensure greater consistency in 
treatment patterns.
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DRUG UTILISATION AND EXPENDITURE ASSOCIATED WITH
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Tesar T, Foltan V, Binder R
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OBJECTIVES: To analyse the utilisation of drugs for treatment of neurological disor-
der (ATC group: N01–N07) within Slovakia between 1999 and 2007 and to asses the
economic consequences of the medications. METHODS: For 1999–2007, the data
about consumption of drugs for treatment of neurological disorder were collected 
following ATC/DDD methodology. Data of wholesalers, who are legally obliged
provide this information to the Slovak Institute for Drug Control, was used for
the analysis. The results were expressed in the numbers of the packages, ﬁ nance units 
(€) and deﬁ ned daily doses per 1000 inhabitants per day (DID). RESULTS: The col-
lected data showed a signiﬁ cant increases in consumption of drugs for treatment of 
neurological disorder from 1999 to 2007 in term of DID (in 1999 (108.92), in 2003
(119.46) and in 2007 (142.57). A large increase in consumption of psychoanaleptics
(in 1999 (16.00), in 2003 (33.22) and in 2007 (44.84) and a stable consumption of 
psycholeptics in 1999 (40.88), in 2003 (38.33) and in 2007 (41.34) in term of DID 
can be seen from this analysis. We can see a slight increase in consumption of drugs 
in term of DID within the group of antiepileptics (in 1999 (4.60), in 2003 (5.25) and
in 2007 (6.86) and anti-parkinson drugs (in 1999 (3.19), in 2003 (3.81) and in 2007 
(3.92). Financial expenditures for psychoanaleptics (in 1999 (€16,613,000), in 2003 
(€40,572,000) and in 2007 (€30,382,000), for psycholeptics (in 1999 (€10,504,000), 
in 2003 (€24,603,000) and in 2007 (€36,502,000) can be seen from this study. CON-
CLUSIONS: Inseparable components of the Slovak drug policy must be viewed real-
istically with regard to the consumption of drugs for neurological disorder. Adherence 
to principles of neurological treatment’s guidelines lead to fundamental short and long
term ﬁ nancial savings within health care systems.
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OBJECTIVES: Cholinesterase (ChE) inhibitors, including donepezil and rivastigmine,
are standard of care for mild to moderate cognitive impairment due to Alzheimer’s 
disease (AD). The current study investigates whether treatment with rivastigmine is
associated with less use of antipsychotics compared to treatment with donepezil. 
METHODS: A claims analysis was conducted from 01/2004 through 12/2006 using
the MedStat MarketScan database. Patients included had continuous insurance cover-
age, had at least 1 diagnosis of AD, and were newly initiated on either rivastigmine
or donepezil after the ﬁ rst AD claim. Patients using memantine or receiving antipsy-
chotics in the time interval of q180 days before and 14 days after the ﬁ rst rivastigmine 
or donepezil drug dispensing were excluded. Both Kaplan-Meier and multivariate Cox 
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regression analyses were conducted to compare the time to ﬁ rst antipsychotic drug 
dispensing between the rivastigmine and donepezil groups. RESULTS: A total of 532 
patients receiving rivastigmine and 7,264 patients receiving donepezil were studied.
The donepezil group was slightly older (81.1 vs. 79.9 years; p  0.0044) with a greater 
proportion of women (59.4% vs. 53.2%; p  0.0053). The Kaplan-Meier analysis 
showed that 30 (5.6%) rivastigmine and 589 (8.1%) donepezil patients received anti-
psychotic medications (Log-rank p  0.0672). Multivariate adjustment showed that 
rivastigmine was associated with a statistically signiﬁ cant reduction in emergent use 
of antipsychotic drugs by 34% relative to donepezil (hazard ratio: 0.66; 95% CI:
0.46–0.96; p  0.0305). Among other statistically signiﬁ cant covariates, older age, 
lower drug dose, baseline depression and neuropsychiatric symptoms, and admission 
to inpatient long-term care facilities were associated with an increased likelihood of 
antipsychotic drug use. CONCLUSIONS: Based on real-world data from a large
cohort of antipsychotic-naïve patients with AD, rivastigmine was found to be associ-
ated with a signiﬁ cant reduction in the emergent use of antipsychotic drugs, compared
to donepezil. Prospective studies are needed to verify these ﬁ ndings.
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OBJECTIVES: We have initiated a project to identify statistically independent dimen-
sions of health services utilization in epilepsy. A desirable covariate for this analysis 
is the type of convulsive disorder. Here we report on the classiﬁ cation of epilepsy 
patients using insurance data. METHODS: We applied an iterative classiﬁ cation
technique to patients’ sequences of insurance claims for outpatient and inpatient ser-
vices, diagnostic procedures and drugs. The target population included 122,850 US
commercial insurance and Medicare supplement subscribers with a physician visit
diagnosis of ICD-9 345xx. We classiﬁ ed persons into the ICD-9 coding scheme (or as 
“not epilepsy”) by developing a family of rules corresponding to empirically observed 
claims patterns. We sampled patient histories in blocks of 50. Within each claims
history, a neuroepidemiologist looked for diagnosis, procedure and treatment patterns
that pointed to a clinical diagnosis, and added that pattern to the rule deﬁ ning a
diagnostic type. Removing classiﬁ ed patients, we sampled remaining claims histories
and repeated the process of classiﬁ cation and removal and sampling until 50 claims 
histories suggested no new classiﬁ cation rules. Remaining patients were tagged as
unclassiﬁ able. Finally, we reviewed samples of the classiﬁ ed patients to identify dis-
qualiﬁ cation criteria. RESULTS: The majority of patients are classiﬁ able and the
empirical classiﬁ cation rules “make sense” clinically (e.g. diagnostic changes are per-
mitted immediately if they follow a diagnostic procedure). A signiﬁ cant minority of 
cases of epilepsy have only nonspeciﬁ c treatment codes assigned. CONCLUSIONS:
There are clear examples of patients with different clinical subtypes of epilepsy in
claims data, and it will be possible to derive average utilization characteristics and
drivers for different types of epilepsy. Analysis of the dimensions of health care utiliza-
tion (combinations of drugs, procedures, physician and hospital) may yield further
insight into currently unclassiﬁ able cases and will provide sensitive measures of the
cost impact of new therapies.
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OBJECTIVES: Generic substitution might produce economic impacts beyond the
reduction in spending for new generic product, such as increased number of users,
and utilization of health care resources. The current study forecasts the economic
impact of generic entry of the antiepileptic drug (AED) topiramate into the settings of 
France, Germany, Italy, and the UK. METHODS: Health claims from Québec’s pro-
vincial health plan (RAMQ) from January 2006 to September 2008, and IMS Health 
data on European AED sales between 1998 and 2008 were used. Patient-level health
care utilization and costs in Canada were calculated during mutually-exclusive periods
of brand versus generic use of topiramate (Topamax). Annualized Canadian health
care costs were projected for periods of branded and generic use in each country 
(€2007/person-year). Using market-level sales, branded and generic topiramate utiliza-
tion were forecasted for 12 months following expected generic entry (September 
2009-September 2010) using autoregressive and panel-data regression models. The 
economic impact of generic entry was projected for each country, stratiﬁ ed into its
effect on market size, topiramate costs, and other health care costs. Budgetary conse-
quences for individual, private, and government payers were assessed. RESULTS:
Projected per-patient health care costs in G4 European countries, excluding topira-
mate, would be signiﬁ cantly higher during generic-use periods (adjusted cost differ-
ences per person-year: €706 to €815, p  0.001 for all comparisons) compared to
brand-use periods. Assuming mandatory generic substitution for all patients, predicted 
system-wide increases in total adjusted health care costs would range from 3.5% (UK)
to 24.4% (France) 1 year after generic entry. Increases in non-topiramate health care
costs (13.7% to 18.1%) would more than offset savings in topiramate costs (–6.3% 
to 13.8%) in France, Italy, and the UK. These impacts would be evenly distributed 
among payers of each country. CONCLUSIONS: Generic entry of topiramate in
Europe would represent a trade-off between reduced generic drug expenditures and 
increased health care costs.
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EXPLORING THE IMPACT OF DISPENSING CHANNEL ON MEDICATION 
ADHERENCE AMONG MULTIPLE SCLEROSIS PATIENTS
Tang J, Faris R
Accredo Health Group, Memphis, TN, USA
OBJECTIVES: To determine if dispending channel (specialty pharmacy versus retail) 
impacts medication adherence for patients receiving therapy for Multiple Sclerosis
(MS). METHODS: Retrospective pharmacy claims for MS patients were extracted for 
2007–2008. Patients were followed for 12 months from the index claim. Adherence 
was measured using a Medication possession ratio (MPR), with patients considered 
adherent if MPR q 80%. Propensity scoring was used in the sample selection. Differ-
ences of demographics were evaluated using the Wilcoxon signed-rank test for con-
tinuous variable and the chi-square test for the categorical variable. Generalize linear
regression was used to calculate the adjusted mean adherence. RESULTS: From a study 
population of 31,593 MS patients, a matched sample of 19,742 was chosen (9,871 in
the specialty and retail channel). There were no differences in demographics between 
the samples, with 76.19% female and mean age of 48.84. Overall comparison showed 
an average MPR of 89.94% for specialty and 84.08% for retail; with 81.52% of 
specialty patients adherent (MPR  80%) vs. 71.18% of retail patients. The results
were similar for each individual MS therapy. The following list the drug, and the 
percent of specialty and retail patients at least 80% adherent: Interferon beta-1a 
(Avonex) 87.49% vs. 78.13%, interferon beta-1a (Rebif) 80.97% vs. 75.50%, inter-
feron beta-1b 79.16% vs. 66.48%, glatiramer acetate 78.26% vs. 63.81%. (Average
MPRs for each drug available on the poster.) All comparisons were statistically sig-
niﬁ cant (P  .05). CONCLUSIONS: Patients who receive their MS medication from 
a specialty pharmacy are much more likely to be adherent than those who receive 
medication from a retail pharmacy. This is true across the broad category, as well as
each individual therapy. Specialty pharmacy offers enhanced patient counseling and 
clinical services, which may explain differences in adherence. Follow up studies will 
explore the impact of improved adherence on clinical and economic outcomes.
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DETECTION OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 
REPORTS ASSOCIATED WITH NATALIZUMAB PRE- AND POST-RISK 
MINIMIZATION ACTION PLAN FROM ADVERSE EVENT REPORTING 
SYSTEM DATABASE
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OBJECTIVES: To review postmarketing surveillance data in order to examine reports 
of progressive multifocal leukoencephalopathy (PML) in patients using natalizumab 
for multiple sclerosis (MS) before and after the implementation of a natalizumab Risk 
Minimization Action Plan (RiskMAP) in the United States (US). METHODS: The 
Adverse Event Reporting System (AERS) database was searched for reports of serious 
adverse events of PML associated with natalizumab in MS patients during the pre- 
(November 23, 2004-February 28, 2005) and post-RiskMAP (July 2006-June 2008)
periods. AERS reports listing, 1) Tysabri or natalizumab as primary suspect drug; 2) 
events of PML; and 3) natalizumab-PML combination reports were extracted. Dupli-
cate reports and drug redundancies were excluded; in the event of duplicate case
reports, the report with the most recent date was used. Reports from foreign countries 
were excluded to focus the analysis on US-related events and to exclude variations 
due to different governmental requirements and national post-marketing surveillance 
systems. RESULTS: A total of 576,072 unduplicated reports were identiﬁ ed during 
the post-RiskMAP period in the US. A hands-on review of the reports of PML and
tysabri/natalizumab identiﬁ ed 41 and 1221 unduplicated US reports respectively, 
during the post-RiskMAP period. There were two conﬁ rmed cases (from previous lit-
erature) of PML associated with natalizumab before RiskMAP implementation and 
eight reported cases following RiskMAP implementation. The mean age of reported
natalizumab-PML cases post-RiskMAP was 50.6 years, and 7 of the cases (87.5%)
were in females. CONCLUSIONS: The extracted reports from the AERS indicate
continuing case reports for PML associated with natalizumab for MS during the post-
RiskMAP period. Although AERS is incapable of detecting the true frequency of an 
adverse event associated with a drug or assessing the actual causal relationship, these
reports of natalizumab-associated PML indicate that continued surveillance and
further epidemiologic study is necessary.
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AN EXPLORATORY STUDY ABOUT THE IMPACT OF THE PATIENT’S
ADHERENCE IN THE TREATMENT COSTS
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OBJECTIVES: To evaluate the impact of the patient’s adherence to national guideline 
in the treatment costs. METHODS: A one-year (January 2007 to December 2007) 
retrospective database search was conducted to identify medication used, costs, patient 
adherence and provision. The source of data was the Ministry of Health public avail-
able database, called DATASUS. The study were conduct in four steps: 1) Determine 
the medicines codes in the public list; 2) Establish the relationships among drugs and
